Dennis O’Neill is the President of BioMediCan, a biotech startup company that has developed a unique patented method of producing pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids, including CBG, CBGA, THCV, THCVA, CBN, CBNA and high-value compounds using a proprietary organic biosynthesis platform at 70-90% lower cost than conventional methods. 

The Cannabinoids 'CBD" Market is experiencing astronomical grow rates expecting the market to be $146 billion by 2026. There are over 200 known Cannabinoids many that are significantly more effective for treating multiple medical conditions than CBD's. The problem is it takes a significant amount of time to produce, is very expensive and there is a limited amounts that can be produced. BioMediCan has developed a bio-synthesized process where they can produce significant quantities that are free from Pesticide's/Contaminants"safer" at a fraction of the cost. We believe that this creates a significant opportunity to develop and sell mass quantities of these rare cannabinoids that are free of THC to the Global Market. BioMedican has a world-class scientific management team and 4 patents pending

Highlights

• How BioMediCan was founded and it’s unique value proposition
• Producing high-quality, low-cost non-THC products that circumvent FDA regulations
• Producing rare cannabinoids 
• Health benefits of CBG, THCV, CBN 

Links of Interest

• Biomedican https://biomedican.com/
• Dennis O’Neill on LinkedIn https://www.linkedin.com/in/oneillcapital/
• CBG and THCV: Beneficial Cannabinoids https://www.cbdschool.com/cbg-thcv-cannabinoids/